The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR-TKIs treatment.

Authors

Van Thuan Nguyen, Ngoc Hoang Le, Nhu Quynh Phan, Toan Trung Duong, Le Thi Anh Thu, Hsuan-Chia Yang, Chih-Wei Huang, Min-Huei Hsu, Jason C Hsu, Chien-Tien Su, Phung-Anh Nguyen

Published in

British journal of clinical pharmacology. Sep 06, 2026. Epub Sep 06, 2026.

Abstract

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have substantially improved outcomes in non-small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1-antihistamines (H1AHs) and clinical outcomes in NSCLC patients undergoing EGFR-TKIs therapy.
We conducted a retrospective cohort study using the Taipei Medical University Clinical Research Database (TMUCRD) linked to the Taiwan Cancer Registry. Patients with advanced NSCLC receiving EGFR-TKI therapy between 1 January 2008 and 31 December 2022 were classified according to concomitant prescription of H1AHs. The primary and secondary endpoints were time to treatment failure (TTF) and all-cause mortality, respectively. Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models. Sensitivity analyses and landmark analyses were performed to evaluate the robustness of the findings.
Among 828 eligible patients, 475 (57.37%) received concomitant H1AHs during EGFR-TKIs therapy, whereas 353 (42.63%) did not. Concomitant prescriptions of H1AHs exhibited a significantly reduced risk of treatment failure (aHR; 0.61, 95% CI; 0.53-0.71, p < .001), corresponding to longer mean TTF (2.09 vs. 1.25 years), as well as a lower risk of all-cause mortality (aHR; 0.36, 95% CI; 0.30-0.44, p < .001). A stronger association was observed in patients with extended durations of H1AHs exposure (≥60 or ≥90 days).
Concomitant prescriptions of H1AHs with EGFR-TKIs therapy were associated with a significantly reduced risk of treatment failure and mortality in patients with advanced NSCLC.

PMID:
42702354
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.